ATE531717T1 - Neue kristalline form eines pyridazinoä4,5- büindolderivats - Google Patents

Neue kristalline form eines pyridazinoä4,5- büindolderivats

Info

Publication number
ATE531717T1
ATE531717T1 AT06813757T AT06813757T ATE531717T1 AT E531717 T1 ATE531717 T1 AT E531717T1 AT 06813757 T AT06813757 T AT 06813757T AT 06813757 T AT06813757 T AT 06813757T AT E531717 T1 ATE531717 T1 AT E531717T1
Authority
AT
Austria
Prior art keywords
büindol
derivative
crystalline form
new crystalline
new
Prior art date
Application number
AT06813757T
Other languages
English (en)
Inventor
William Rocco
John Higgins
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE531717(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Application granted granted Critical
Publication of ATE531717T1 publication Critical patent/ATE531717T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT06813757T 2005-08-29 2006-08-24 Neue kristalline form eines pyridazinoä4,5- büindolderivats ATE531717T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71215305P 2005-08-29 2005-08-29
PCT/US2006/033254 WO2007027525A1 (en) 2005-08-29 2006-08-24 Novel crystalline form of a pyridazino [4 , 5-b] indole derivative

Publications (1)

Publication Number Publication Date
ATE531717T1 true ATE531717T1 (de) 2011-11-15

Family

ID=37546937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06813757T ATE531717T1 (de) 2005-08-29 2006-08-24 Neue kristalline form eines pyridazinoä4,5- büindolderivats

Country Status (32)

Country Link
US (1) US7683062B2 (de)
EP (1) EP1924585B1 (de)
JP (1) JP5063600B2 (de)
KR (2) KR20080050577A (de)
CN (1) CN101253176B (de)
AR (1) AR057099A1 (de)
AT (1) ATE531717T1 (de)
AU (1) AU2006285142B2 (de)
BR (1) BRPI0615259A2 (de)
CA (1) CA2619284C (de)
CR (1) CR9723A (de)
CY (1) CY1112317T1 (de)
DK (1) DK1924585T3 (de)
EA (1) EA014164B1 (de)
EC (1) ECSP088209A (de)
ES (1) ES2375841T3 (de)
HK (1) HK1123794A1 (de)
HR (1) HRP20120073T1 (de)
IL (1) IL189276A (de)
MA (1) MA30000B1 (de)
NO (1) NO20081365L (de)
NZ (1) NZ566087A (de)
PL (1) PL1924585T3 (de)
PT (1) PT1924585E (de)
RS (1) RS52318B (de)
SI (1) SI1924585T1 (de)
TN (1) TNSN08059A1 (de)
TW (1) TW200813060A (de)
UA (1) UA91716C2 (de)
UY (1) UY29771A1 (de)
WO (1) WO2007027525A1 (de)
ZA (1) ZA200801890B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536210A (ja) * 2003-11-17 2007-12-13 メルック・エプロバ・アクチエンゲゼルシヤフト (6r)−l−エリスロ−テトラヒドロビオプテリンジヒドロクロライドの結晶形
JP2008501657A (ja) * 2004-06-02 2008-01-24 サンド・アクチエンゲゼルシヤフト 結晶形態のメロペネム中間体
BRPI0616040A2 (pt) * 2005-09-21 2011-06-07 Nycomed Gmbh cloridrato de sulfonilpirról como inibidor de histona desacetilases
EP1951700A2 (de) * 2005-10-31 2008-08-06 Janssen Pharmaceutica N.V. Neue verfahren für die herstellung von piperazinyl- und diazapanylbenzamidderivaten
EP2044020B1 (de) * 2006-06-16 2011-05-04 H. Lundbeck A/S Kristalline formen von 4-[2-(4-methylphenylsulfanyl)phenyl]piperidin mit kombinierter serotonin- und norepinephrinwiederaufnahmehemmung zur behandlung neuropathischer schmerzen
MX2009003913A (es) * 2006-10-27 2009-04-24 Signal Pharm Llc Formas solidas que comprenden 4-[9-(tetrahidro-furano-3-il)-8-(2,4 ,6-trifluoro-fenilamino)-9h-purin-2-ilamino]-ciclohexan-1-ol, composiciones de las mismas, y su uso.
EP2085397A1 (de) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Kristalline Form von Abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
KR20110052640A (ko) * 2008-08-18 2011-05-18 사노피-아벤티스 유.에스. 엘엘씨 7-클로로-N,N,5-트리메틸-4-옥소-3-페닐-3,5-디하이드로-4H-피리다지노[4,5-b]인돌-1-아세트아미드의 다형체의 제조방법
NZ601967A (en) 2010-03-12 2015-03-27 Omeros Corp Pde10 inhibitors and related compositions and methods
EP2611433A2 (de) * 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Nicht-hygroskopische salze aus 5-ht2c-agonisten
WO2013044816A1 (en) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
EP3285760A4 (de) 2015-04-24 2018-09-26 Omeros Corporation Pde10-hemmer sowie entsprechende zusammensetzungen und verfahren
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Pde10阻害剤の固体状態形態
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2829939B3 (fr) 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
WO2005034999A2 (en) 2003-10-10 2005-04-21 Bvm Holding Co. Composition comprising association complex of a pharmaceutical and a poloxamer

Also Published As

Publication number Publication date
HRP20120073T1 (hr) 2012-07-31
CR9723A (es) 2008-06-18
DK1924585T3 (da) 2012-02-27
IL189276A (en) 2012-07-31
EP1924585B1 (de) 2011-11-02
ES2375841T3 (es) 2012-03-06
EA200800716A1 (ru) 2008-08-29
HK1123794A1 (en) 2009-06-26
US7683062B2 (en) 2010-03-23
CA2619284A1 (en) 2007-03-08
JP2009506116A (ja) 2009-02-12
EP1924585A1 (de) 2008-05-28
EA014164B1 (ru) 2010-10-29
CY1112317T1 (el) 2015-12-09
KR20080050577A (ko) 2008-06-09
PL1924585T3 (pl) 2012-08-31
SI1924585T1 (sl) 2012-09-28
UA91716C2 (ru) 2010-08-25
JP5063600B2 (ja) 2012-10-31
US20080139569A1 (en) 2008-06-12
NO20081365L (no) 2008-04-03
CN101253176A (zh) 2008-08-27
ECSP088209A (es) 2008-06-30
AU2006285142B2 (en) 2012-06-14
MA30000B1 (fr) 2008-12-01
ZA200801890B (en) 2009-11-25
CN101253176B (zh) 2012-04-18
PT1924585E (pt) 2012-01-19
AR057099A1 (es) 2007-11-14
UY29771A1 (es) 2007-03-30
CA2619284C (en) 2014-04-29
KR20130087059A (ko) 2013-08-05
NZ566087A (en) 2011-03-31
TW200813060A (en) 2008-03-16
BRPI0615259A2 (pt) 2011-05-17
RS52318B (en) 2012-12-31
IL189276A0 (en) 2008-08-07
AU2006285142A1 (en) 2007-03-08
WO2007027525A1 (en) 2007-03-08
TNSN08059A1 (en) 2009-07-14

Similar Documents

Publication Publication Date Title
ATE531717T1 (de) Neue kristalline form eines pyridazinoä4,5- büindolderivats
LTC2343304I2 (lt) Biocidiniai boronoftalido junginiai
DK1902037T3 (da) 2,4-diamino-pyrimidiner som auroainhibitorer
ATE481383T1 (de) 3-aza-bicycloä3.1.0ühexanderivate
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
NL1031385A1 (nl) Gesubstitueerde sulfonylaminoarylmethylcyclopropaancarbonamideverbindingen.
DE602005005306D1 (de) Steuerung der Bahn eines Greifers
HRP20120323T1 (en) Diarylhydantoin compounds
DK3275965T3 (da) Sammensætninger, der omfatter en fluorolefin
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
DE602006005030D1 (de) Phasenaustauschtinten
ATE502012T1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivat
NL1031335A1 (nl) Gesubstitueerde N-sulfonylaminofenylethyl-2-fenoxyaceetamideverbindingen.
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
ATE487691T1 (de) Acetylenderivate
NL1032046A1 (nl) Prostaglandinederivaten.
BRPI0815059A2 (pt) Derivado de 1,3-di-hidroisoindol
DK1963295T3 (da) 3,6-dihydro-2-oxo-6H-(1,3,4)thiazinderivater
NL2000937A1 (nl) Piperidinederivaten.
TWI315670B (en) Substituted aryl 1,4-pyrazine derivatives
ATE445604T1 (de) Neue 2,6-diaminopyridin-3-on-derivate
ITMO20050015A1 (it) 'essiccatoio a spruzzo perfezionato.
BRPI0818848A2 (pt) Compostos de 2,3-di-idro-benzofurano
DK1932835T3 (da) Fremgangsmåde til fremstilling af 2,3-dihydropyridazinforbindelse
FR2871375B1 (fr) Compositions tinctoriales comprenant un derive de 1,2-indanedione